Adenosine Acts Through A2AR to Alleviate the Inflammatory Response Caused by Activation of Perivascular-Resident Macrophage-Like Melanocytes
Related Experiment Video
Updated: Jan 13, 2026

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
Wenya Fan1, Jiale Lv1, Lingling Neng1
1Department of Otorhinolaryngology, Head and Neck Surgery, The First Affiliated Hospital of Zhengzhou University, 450052 Zhengzhou, Henan, China.
Background:
Disruption of the blood labyrinth barrier (BLB) is considered a pathological cause of diverse hearing impairments. Perivascular-resident macrophage-like melanocytes (PVM/Ms) play a critical role in maintaining inner ear homeostasis and BLB integrity. Activation of PVM/Ms leads to decreased production of pigment epithelium-derived factor (PEDF), contributing to BLB breakdown. This study investigated the role of the adenosine A2A receptor (A2AR) pathway in lipopolysaccharide (LPS)-induced inflammation in PVM/Ms and elucidated the underlying mechanisms.
Methods:
The anti-inflammatory effects of adenosine and its specific receptor A2AR were evaluated in LPS-induced PVM/Ms. The levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and tissue inhibitor of matrix metalloproteinase 1 (TIMP-1) were measured by quantitative real-time PCR (qRT-PCR) and enzyme linked immunosorbent assay (ELISA). Additionally, matrix metalloproteinase-9 (MMP-9) and PEDF were quantified using western blot and ELISA, respectively. An endothelial cell (EC)-PVM/M co-culture model exposed to LPS was established and treated with adenosine and SCH58261 to assess effects on BLB permeability.
Results:
LPS treatment significantly changed the production of inflammatory factors, including IL-6 and TNF-α, as well as MMP-9, TIMP-1, and PEDF. These changes were abrogated by adenosine, which also reduced the production of reactive oxygen species (ROS) and inhibited the activation of PVM/Ms. SCH58261 partially reversed the effects of adenosine following LPS treatment. The p38 MAPK pathway was found to be involved in adenosine regulation of LPS-induced PVM/Ms.
Conclusions:
Adenosine attenuates the inflammatory activation of PVM/Ms and enhances their ability to maintain endothelial barrier integrity by binding to A2AR. The findings support adenosine and A2AR as potential therapeutic targets for treating hearing impairments.
Insights
Adenosine, acting through the A2A receptor (A2AR), reduces inflammation in inner ear cells. This finding suggests A2AR as a potential target for treating hearing impairments caused by blood labyrinth barrier disruption.
Area of Science:
- Inner ear biology
- Neuroimmunology
- Otopathology
Background:
- Disruption of the blood labyrinth barrier (BLB) is a key factor in hearing loss.
- Perivascular-resident macrophage-like melanocytes (PVM/Ms) are crucial for BLB integrity.
- PVM/Ms activation decreases pigment epithelium-derived factor (PEDF), leading to BLB breakdown.
Purpose of the Study:
- Investigate the role of the adenosine A2A receptor (A2AR) pathway in lipopolysaccharide (LPS)-induced inflammation in PVM/Ms.
- Elucidate the mechanisms underlying A2AR's effect on PVM/Ms and BLB integrity.
Main Methods:
- Evaluated adenosine and A2AR effects on LPS-induced PVM/Ms.
- Quantified inflammatory markers (TNF-α, IL-6, TIMP-1, MMP-9) and PEDF using qRT-PCR, ELISA, and Western blot.
- Assessed BLB permeability in an EC-PVM/M co-culture model.
Main Results:
- Adenosine treatment abrogated LPS-induced changes in inflammatory factors and MMP-9.
- Adenosine reduced reactive oxygen species (ROS) and PVM/Ms activation.
- The p38 MAPK pathway was implicated in adenosine's regulatory effects.
Conclusions:
- Adenosine, via A2AR, attenuates PVM/Ms inflammatory activation and enhances endothelial barrier integrity.
- Adenosine and A2AR represent potential therapeutic targets for hearing impairments.
More Related Videos
04:43Author Spotlight: Insights and Innovations in Gene Expression Manipulation Techniques for Choroid Plexus Research
Published on: June 16, 2023
06:43Increased Recovery Time and Decreased LPS Administration to Study the Vagus Nerve Stimulation Mechanisms in Limited Inflammatory Responses
Published on: March 29, 2017
Related Concept Videos
Adrenergic Receptors: ɑ Subtype
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenergic Agonists: Therapeutic Uses
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
Adrenergic Receptors: β Subtype
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Adrenergic Agonists: Direct-Acting Agents
These agents can be classified...
Adrenergic Receptors (Adrenoceptors): Classification
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...